IMUX · Immunic, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $81.98M | $80.05M | $83.22M | $71.25M | $61.12M | $38.64M |
| SG&A | $21.25M | $18.01M | $16.01M | $15.26M | $13.30M | $10.33M |
| Total Operating Expenses | $103.23M | $98.05M | $99.22M | $119.49M | $91.67M | $48.97M |
| D&A | $168.0K | $134.0K | $111.0K | $77.0K | $85.0K | $39.0K |
| Operating Income | ($103.23M) | ($98.05M) | ($99.22M) | ($119.49M) | ($91.67M) | ($48.97M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($97.17M) | ($100.51M) | ($93.61M) | ($120.41M) | ($92.94M) | ($44.02M) |
| EPS - Basic | ($6.20) | ($10.00) | ($21.10) | ($37.80) | ($28.10) | - |
| EPS - Diluted | ($6.20) | ($10.00) | ($21.10) | ($37.80) | ($28.10) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.48M | $35.67M | $46.67M | $106.75M | $86.86M | $127.45M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $10.14M | $7.85M | $5.10M | $4.28M | $3.75M | $3.70M |
| Current Assets | $22.87M | $39.33M | $52.53M | $125.86M | $104.99M | $133.75M |
| Total Assets | $24.05M | $40.87M | $54.30M | $127.75M | $139.10M | $167.86M |
| Current Liabilities | $30.62M | $22.18M | $24.73M | $13.08M | $11.40M | $8.40M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $30.73M | $22.44M | $25.37M | $14.07M | $11.98M | $9.08M |
| Stockholders' Equity | ($6.67M) | $18.43M | $28.93M | $113.68M | $127.11M | $158.78M |
| Retained Earnings | ($608.57M) | ($511.40M) | ($410.89M) | ($317.28M) | ($196.87M) | ($103.93M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($85.81M) | ($84.77M) | ($70.83M) | ($65.14M) | ($83.23M) | ($46.12M) |
| Investing Cash Flow | ($161.0K) | ($264.0K) | $9.46M | ($9.74M) | ($67.0K) | ($146.0K) |
| Financing Cash Flow | $65.58M | $74.54M | $1.03M | $95.76M | $42.84M | $144.43M |
| CapEx | $161.0K | $264.0K | $334.0K | $112.0K | $67.0K | $146.0K |
| Free Cash Flow | ($85.97M) | ($85.03M) | ($71.16M) | ($65.26M) | ($83.30M) | ($46.27M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.88 | 0.85 | 0.76 | 0.54 | 0.90 | 1.05 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -404.0% | -245.9% | -172.4% | -94.2% | -66.8% | -26.2% |
| Return on equity | 1456.2% | -545.4% | -323.6% | -105.9% | -73.1% | -27.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.75 | 1.77 | 2.12 | 9.62 | 9.21 | 15.93 |
| Quick ratio | 0.75 | 1.77 | 2.12 | 9.62 | 9.21 | 15.93 |
| Cash ratio | 0.51 | 1.61 | 1.89 | 8.16 | 7.62 | 15.18 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -3.60 | 2.22 | 1.88 | 1.12 | 1.09 | 1.06 |
| Liabilities / Assets | 1.28 | 0.55 | 0.47 | 0.11 | 0.09 | 0.05 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 54.4x | 23.0x | 3.9x | 11.8x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -5.3% | 1.2% | 17.0% | -30.4% | -87.2% | -32.2% |
| Net income growth (YoY) | 3.3% | -7.4% | 22.3% | -29.5% | -111.2% | -26.0% |
| EPS growth (YoY) | 38.0% | 52.6% | 44.2% | -34.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -1.1% | -19.5% | -9.1% | 21.7% | -80.0% | -61.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -36.3% | -74.6% | -10.6% | -19.9% | 172.1% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IMMUNIC against the 5 most active filers in the same SIC group.